Boster Immunoleader

antibody

Anti-TRIF Antibody

PA2001

100 ug/vial

200 USD

polyclonal

rabbit

Anti-TRIF Antibody

PA2001

Polyclonal

Rabbit IgG polyclonal antibody for TIR domain-containing adapter molecule 1(TICAM1) detection. Tested with WB in Mouse.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: mouse

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Mouse

WB: The detection limit for TICAM1 is approximately 0.5ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the C-terminus of mouse TRIF(693-708aa NNHMWGHTGAQSSDDK).

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

TICAM1(TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 1), also known as TRIF, is an adapter in responding to activation of toll-like receptors(TLRs). It mediates the rather delayed cascade of two TLR-associated signaling cascades, where the other one is dependent upon a MyD88 adapter. By genomic sequence analysis, Oshiumi et al.(2003) mapped the TICAM1 gene to chromosome 19p13.3. By coimmunoprecipitation analysis, Oshiumi et al.(2003) showed that TICAM1 interacts specifically with TLR3, but not with other TLRs. Functional analysis showed that the association of TLR3 and TICAM1 mediates dsRNA activation of IFNB, through either NFKB, AP1, or IRF3. TICAM1 activation of NFKB was found to occur predominantly through IRAK1 rather than IRAK2 . Small interfering(si)RNA blockage of TICAM1, just upstream of the TIR domain, reduced IFNB production in response to dsRNA.

1. Carty, M., Goodbody, R., Schroder, M., Stack, J., Moynagh, P. N., Bowie, A. G.The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.Nature Immun. 7: 1074-1081, 2006. 2. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., Seya, T.TICAM-I, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.Nature Immun. 4: 161-167, 2003. 3. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., Akira, S.Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.J. Immun. 169: 6668-6672, 2002.

TICAM1

TIR domain-containing adapter molecule 1

toll-like receptor adaptor molecule 1

MGC35334 antibody Proline rich vinculin and TIR domain containing protein B antibody Proline-rich antibody PRVTIRB antibody Putative NF kappa B activating protein 502H antibody Putative NF-kappa-B-activating protein 502H antibody Putative NFkB activating protein antibody TCAM1_HUMAN antibody TICAM 1 antibody TICAM-1 antibody TICAM1 antibody TIR domain containing adapter molecule 1 antibody TIR domain containing adapter protein inducing IFN beta antibody TIR domain containing adaptor inducing interferon beta antibody TIR domain-containing adapter molecule 1 antibody TIR domain-containing adapter protein inducing IFN-beta antibody Toll interleukin 1 receptor domain containing adapter protein inducing interferon beta antibody Toll like receptor adaptor molecule 1 antibody Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta antibody TRIF antibody TRIF protein antibody vinculin and TIR domain-containing protein B antibody

Q80UF7